Loading...

These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
Third-party tested for purity, identity, and quantity.
This sermorelin is supplied as a lyophilized (freeze-dried) white powder with a minimum purity of ≥98% as assessed by high-performance liquid chromatography (HPLC). Mass spectrometry confirmation of molecular identity is performed on each lot. A certificate of analysis (CoA) is available upon request.
Sermorelin has been studied across a range of preclinical research models including primary rat and mouse pituitary cell cultures, immortalized somatotroph cell lines, in vivo rodent and primate neuroendocrine models, and cell lines expressing GHRHR. It has also been applied in electrophysiology and neurochemical assays investigating hypothalamic GHRH neuron activity.
No. This product is supplied strictly for in vitro and preclinical laboratory research purposes only. It is not approved, intended, or formulated for human or veterinary administration, self-experimentation, or any clinical application. All research use must comply with applicable institutional and regulatory guidelines.
Sermorelin acts as an agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor (GPCR). Laboratory research examines Gαs-coupled adenylyl cyclase, intracellular cAMP, and PKA signaling associated with this receptor in somatotroph cell models. The peptide corresponds to residues 1–29 of native GHRH and is commonly used as a reference agonist in GHRHR research.
Quality controlled from start to finish. No outsourcing.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29). Supplied as a research reagent for in vitro laboratory assays only; not for human or animal use.